Bayer Schering Pharma of Berlin and Hamamatsu Photonics of Hamamatsu, Japan, have signed a licensing agreement to share their products and expertise in molecular imaging for cancer.
Under the pact, Bayer Schering Pharma will acquire the worldwide exclusive rights for research, development, and commercialization of a group of molecules that specifically bind to malignant tumor cells.
The tracers are labeled with a short-life radionuclide and can be employed for PET imaging. These new PET tracers could help enhance the differentiation of malignant tumors from benign tissue alterations and allow more precise staging of cancer.
Copyright © 2009 AuntMinnie.com